Rothblatt (United Therapeutics) sells $5.3m in UTHR stock
Martine Rothblatt, Chairperson & CEO of United Therapeutics Corp (NASDAQ: UTHR), recently sold approximately $5.3 million worth of company stock through a pre-arranged trading plan. On the same day, Rothblatt exercised stock options, acquiring additional shares. This activity follows positive news for United Therapeutics regarding its Phase 3 TETON-1 trial, which has led several analyst firms to raise their price targets for UTHR.
Perpetual Ltd Makes New Investment in United Therapeutics Corporation $UTHR
Perpetual Ltd initiated a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the fourth quarter, acquiring 2,174 shares valued at approximately $1.06 million. This investment comes as United Therapeutics reported strong Q4 EPS, beating estimates, though revenue slightly missed expectations. Despite significant insider selling totaling over $171.7 million in the last three months, institutional ownership remains high at 94.08%, with analysts maintaining a "Moderate Buy" consensus and an average price target of $586.
Element Squared LLC Acquires New Position in United Therapeutics Corporation $UTHR
Element Squared LLC recently initiated a new stake in United Therapeutics Corporation (UTHR), purchasing 5,027 shares valued at approximately $2.45 million, making it their 21st largest holding. Analysts largely maintain a "Moderate Buy" consensus rating with an average target of $586, fueled by positive Phase-3 clinical data for Tyvaso and strong EPS beats, despite some insider selling activity. The company's financials show a net margin of 41.94% and a P/E ratio of 20.24, with analysts expecting 24.48 EPS for the current year.
Allspring Global Investments Holdings LLC Has $52.05 Million Stock Holdings in United Therapeutics Corporation $UTHR
Allspring Global Investments Holdings LLC significantly increased its stake in United Therapeutics Corporation, now holding 104,785 shares valued at $52.05 million. This coincides with positive Phase 3 clinical trial results for Tyvaso, leading to analyst upgrades and a "Moderate Buy" consensus rating for UTHR stock. Despite recent insider selling, institutional investors own a substantial portion of the company.
Why Is United Therapeutics Stock Soaring Monday?
United Therapeutics (NASDAQ: UTHR) stock surged after its nebulized Tyvaso (treprostinil) met the primary endpoint in the TETON-1 Phase 3 study for idiopathic pulmonary fibrosis (IPF), significantly improving forced vital capacity. The company plans to seek priority review from the FDA for a supplemental New Drug Application to add IPF to Tyvaso's labeled indications. This positive news follows another recent success with their drug ralinepag, which reduced clinical worsening events in pulmonary arterial hypertension patients during its Phase 3 ADVANCE OUTCOMES study.
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan
United Therapeutics (UTHR) CEO Martine Rothblatt exercised options for 9,500 shares and subsequently sold them in open-market transactions on March 30, 2026, under a pre-arranged 10b5-1 trading plan. The transactions involved exercising options at $146.03 per share and selling shares between approximately $581-$603, totaling a net sale of $5.61 million. This activity is considered routine diversification, with Rothblatt retaining substantial direct and indirect holdings in the company.
UNITED THERAPEUTICS (UTHR) director exercises options and sells 1,300 shares under 10b5-1 plan
Christopher Causey, a director at UNITED THERAPEUTICS Corp (UTHR), exercised stock options for 1,300 shares at $119.76 per share and simultaneously sold 1,300 shares at $604.64 per share. These transactions, executed on March 30, 2026, were pre-planned under a Rule 10b5-1 trading plan established on September 30, 2025. Following these trades, Causey directly holds 4,190 shares of Common Stock.
Retirement Systems of Alabama Has $47.39 Million Stock Holdings in United Therapeutics Corporation $UTHR
Retirement Systems of Alabama reduced its holding in United Therapeutics Corporation (NASDAQ:UTHR) by 3.0% in Q4, now owning 97,268 shares valued at $47.39 million. Despite positive news like successful Phase 3 trials and board-authorized buybacks, which have led to analyst price target increases, significant insider selling from the CEO and CFO raises investor concern. Institutional investors collectively own 94.08% of the company's stock.
United Therapeutics Corp (UTHR) Stock Price Up 13.08% on Mar 30
United Therapeutics Corp (UTHR) stock surged by 13.08% in mid-day trading on March 30, reaching an intraday high of $607.89 before closing at $591.21. This places the stock just below its 52-week high, with a significant increase from its 52-week low. Wall Street analysts provide an average target price of $592.80, suggesting an "Outperform" status, although GuruFocus estimates a potential downside based on its GF Value.
United Therapeutics (NASDAQ: UTHR) proposed sale of 1,300 shares via option
United Therapeutics Corporation (NASDAQ: UTHR) has filed a Form 144 notice indicating a proposed sale of 1,300 shares of common stock through a stock option exercise scheduled for March 30, 2026. The filing also details prior open-market dispositions by Christopher Causey in early 2026. This regulatory notice transparently outlines the intent to sell these shares.
United Therapeutics Rises on Positive Study for Cornerstone Drug. Why Shares Could Run Even Higher.
United Therapeutics Corp. (UTHR) saw its shares rise significantly on Monday following positive results from a second Phase 3 clinical trial. The study focused on a nebulized version of its primary drug, Tyvaso, highlighting improved outcomes. This development suggests potential for further growth in the stock.
United Therapeutics shares surge after positive IPF trial results
United Therapeutics shares surged over 13% after positive topline results from the Phase 3 TETON‑1 trial for its inhaled drug, Tyvaso, in idiopathic pulmonary fibrosis (IPF). Analysts are highly optimistic about Tyvaso's potential to become the new standard of care, with Jefferies estimating a market opportunity of $5 to 10 billion. The company plans to submit a supplemental New Drug Application by summer 2026.
United Therapeutics Corporation (UTHR) Surges 14.8% to $600.09
United Therapeutics Corporation (UTHR) saw its stock surge by 14.8% to $600.09 following significant insider buying, totaling $12.4 million from its executives and board members. CEO Martine A. Rothblatt led the purchases, signaling strong confidence in the company's future. Investors are now watching for potential pipeline updates, regulatory milestones, or partnership announcements that could further impact the stock.
United Therapeutics Corporation Announces Teton-1 Pivotal Study Of Tyvaso® Meets Primary Endpoint For Treatment Of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen In Teton-2
United Therapeutics Corporation announced that its Teton-1 pivotal study of Tyvaso® successfully met its primary endpoint for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This positive outcome reportedly exceeded the impressive treatment effect observed in the previous Teton-2 study. The news was reported by Refinitiv.
TD Cowen raises United Therapeutics stock price target on trial win
TD Cowen has increased its price target for United Therapeutics (NASDAQ:UTHR) to $660 from $575, maintaining a Buy rating, following positive results from the TETON-1 Phase III study for Tyvaso in idiopathic pulmonary fibrosis. The study met its primary endpoint, showing a significant benefit, leading other analysts like Jefferies and Cantor Fitzgerald to reiterate or raise their own price targets. United Therapeutics plans to submit a supplemental new drug application, with full trial data to be presented at an upcoming conference.
United Therapeutics Corporation announces Teton-1 pivotal study of Tyvaso meets primary endpoint for treatment of idiopathic pulmonary fibrosis, exceeding impressive treatment effect seen in Teton-2
United Therapeutics Corporation announced that its Teton-1 pivotal study of Tyvaso (treprostinil) met its primary endpoint for the treatment of idiopathic pulmonary fibrosis (IPF). This positive outcome reportedly exceeded the treatment effect observed in a previous study, Teton-2. The news highlights a significant development for the pharmaceutical company and potentially for patients suffering from IPF.
Tyvaso beats placebo, improves lung capacity in fibrosis study
United Therapeutics announced that its TETON-1 study for nebulized Tyvaso in treating idiopathic pulmonary fibrosis (IPF) met its primary endpoint, showing superiority over placebo in improving forced vital capacity and reducing clinical worsening. Integrated analysis with the TETON-2 study confirmed statistically significant treatment effects across most efficacy endpoints. The company plans to seek priority review for a supplemental New Drug Application with the FDA by summer's end to add IPF to Tyvaso's labeled indications.
Rothblatt sells $5.09 million in United Therapeutics (UTHR) stock
Martine Rothblatt, Chairperson & CEO of United Therapeutics (NASDAQ:UTHR), sold 9,500 shares of common stock for approximately $5.09 million on March 26, 2026, after exercising stock options for the same number of shares. These transactions were conducted under a pre-arranged 10b5-1 trading plan. The company also recently announced positive phase 3 study results for nebulized Tyvaso, a new $2 billion stock repurchase program, and received reiterated "Buy" ratings from analysts with increased price targets.
Wedge Capital Management L L P NC Has $29.57 Million Holdings in United Therapeutics Corporation $UTHR
Wedge Capital Management L L P NC recently reduced its stake in United Therapeutics Corporation by 8.8% in Q4, now holding 60,687 shares worth $29.57 million. Despite beating Q4 EPS expectations, United Therapeutics missed revenue estimates, though analysts maintain a "Moderate Buy" consensus. Insider selling was significant, with executives selling shares totaling $176.8 million, while institutional investors and hedge funds combined own 94.08% of the company's stock.
United Therapeutics Corporation $UTHR Shares Acquired by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC significantly increased its stake in United Therapeutics Corporation ($UTHR) by 123.7% during the fourth quarter, now owning 14,971 shares worth $7.624 million. Other institutional investors also adjusted their positions, and hedge funds now hold a substantial 94.08% of the company. Despite strong Q4 earnings per share that beat estimates, the company's revenue missed expectations, and several insiders, including the COO and CFO, have sold a considerable number of shares recently. Analysts, however, have largely maintained "buy" ratings and raised price targets, with a consensus around a "Moderate Buy" rating and a target price of $549.91.
Cantor Fitzgerald Raises United Therapeutics (UTHR) Price Target to $625
Cantor Fitzgerald has increased its price target for United Therapeutics (UTHR) to $625 from $525, maintaining an Overweight rating, primarily due to the potential of its idiopathic pulmonary fibrosis treatment. The analyst expects significant upside if the TETON-1 clinical trial delivers positive results. United Therapeutics has also authorized a new $2 billion stock repurchase program, commencing with an initial $1.5 billion accelerated share repurchase.
Assenagon Asset Management S.A. Buys 3,824 Shares of United Therapeutics Corporation $UTHR
Assenagon Asset Management S.A. increased its stake in United Therapeutics Corporation by 18.4% in Q4, acquiring 3,824 additional shares to own 24,628 shares valued at $12 million. Despite this, company insiders, including EVP Paul Mahon and CFO James Edgemond, sold off substantial amounts of stock, totaling 356,320 shares worth $176.8 million. United Therapeutics reported mixed Q4 results with EPS beating estimates but revenue falling short, and analysts currently hold a "Moderate Buy" rating with an average target price of $549.91.
Cantor Fitzgerald Raises United Therapeutics (UTHR) Price Target to $625
Cantor Fitzgerald has increased its price target for United Therapeutics (UTHR) to $625 from $525, maintaining an "Overweight" rating. This decision is driven by the potential for significant upside if the company's TETON-1 clinical trial for idiopathic pulmonary fibrosis yields positive results. Additionally, United Therapeutics recently authorized a new $2 billion stock repurchase program, including an initial $1.5 billion accelerated share repurchase.
Vanguard (UTHR) amendment shows 0 shares after internal realignment
Vanguard Group has filed an amendment (SCHEDULE 13G/A) for United Therapeutics (UTHR) reporting 0 shares beneficially owned and 0% ownership as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, which led to certain Vanguard subsidiaries reporting their beneficial ownership separately in accordance with SEC Release No. 34-39538. Previously aggregated holdings will now be disaggregated and reported by individual subsidiaries.
Rothblatt sells $5.09 million in United Therapeutics (UTHR) stock
Martine Rothblatt, Chairperson & CEO of United Therapeutics Corp (NASDAQ:UTHR), sold 9,500 shares of common stock for approximately $5.09 million on March 26, 2026, while also exercising stock options. This sale was part of a pre-arranged 10b5-1 trading plan. The article also mentions United Therapeutics' positive phase 3 TETON-2 study results, a new $2 billion stock repurchase program, and recent analyst rating upgrades.
United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?
United Therapeutics (UTHR) has seen its shares rise 5.7% since its last earnings report, outperforming the S&P 500. The company reported better-than-expected Q4 2025 EPS, driven by strong product sales from Tyvaso and Orenitram, though overall revenues missed estimates. Despite a downward trend in recent estimates and a "Hold" Zacks Rank, the company anticipates double-digit revenue growth in 2026 and aims for a $4 billion annualized revenue run rate by the second half of 2027.
Rothblatt, United Therapeutics CEO, sells $5.1m in UTHR stock
Martine Rothblatt, Chairperson & CEO of United Therapeutics Corp (NASDAQ:UTHR), sold approximately $5.1 million worth of company stock on March 25, 2026, while also exercising stock options for 9,500 shares. These transactions were executed under a pre-arranged 10b5-1 trading plan. The article also highlights recent company news, including a $2 billion share repurchase program and positive results from a phase 3 study for nebulized Tyvaso.
Rothblatt, United Therapeutics CEO, sells $5.1m in UTHR stock
Martine Rothblatt, Chairperson & CEO of United Therapeutics Corp, sold approximately $5.1 million in company stock on March 25, 2026, while also exercising stock options worth about $1.39 million. These transactions were part of a pre-arranged 10b5-1 trading plan. The company also announced a $2 billion stock repurchase program and positive results from its Phase 3 TETON-2 study, leading to raised price targets from analysts.
Assessing United Therapeutics (UTHR) Valuation As Organ Programs Shape Its 2026 Narrative
United Therapeutics (UTHR) is gaining investor attention with strong share price performance and is currently valued below its fair value. The company's 2026 narrative is heavily influenced by its "Organ Manufacturing" milestone, aiming to cure lung disease through organ replacement. Despite legal and safety risks, the company's growing revenue, strong margins, and bold organ programs suggest an undervalued position with significant upside potential.
United Therapeutics stock hits all-time high at 548.43 USD
United Therapeutics stock (UTHR) has reached an all-time high of $548.43, reflecting a 75.94% increase over the past year and strong investor confidence despite being considered overvalued by InvestingPro analysis. The company's financial health is rated as "GREAT" with an 88% gross profit margin, supported by recent strategic moves like a $2 billion stock repurchase program and positive results from its TETON-2 study for idiopathic pulmonary fibrosis. Analysts like TD Cowen and Cantor Fitzgerald have reiterated 'Buy' ratings and raised price targets, underscoring growth potential and successful initiatives.
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor
Judy Olian, a Director at United Therapeutics Corp (UTHR), sold 200 shares of the company on March 23, 2026, bringing her total ownership to 4,245 shares. This sale is part of a trend for Olian, who has sold 2,600 shares over the past year with no purchases, contributing to a total of 148 insider sells versus 0 insider buys for UTHR in the same period. The stock is currently trading at $530, and GuruFocus estimates it to be significantly overvalued with a price-to-GF-Value ratio of 1.4.
UTHR (UTHR): Judy Olian to sell 200 shares under Form 144 notice
Judy Olian has filed a Form 144 notice to sell 200 shares of United Therapeutics Corp (UTHR) common stock. These shares are restricted stock acquired on June 26, 2021. The filing also discloses previous sales by Olian of 200 shares each on March 2, March 9, and March 16, 2026, with proceeds totaling over $310,000.
Rothblatt, United Therapeutics CEO, sells $4.9m in UTHR stock
Martine Rothblatt, Chairperson & CEO of United Therapeutics Corp (NASDAQ:UTHR), recently sold 9,500 shares of company stock totaling nearly $5 million, while also exercising options to acquire an equal number of shares. These transactions were executed under a pre-arranged 10b5-1 trading plan. Following these sales, Rothblatt directly owns 40,513 shares, with additional indirect ownership through various trusts.
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares under 10b5-1 plan
United Therapeutics (UTHR) Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares at $146.03 and simultaneously sold these 9,500 shares in open-market transactions at prices exceeding $520 per share. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these sales, Rothblatt directly holds 40,513 common shares, with additional indirect holdings through her spouse and trusts.
[144] UNITED THERAPEUTICS Corp SE... | UTHR SEC Filing - Form 144
This article reports on a Form 144 SEC filing by United Therapeutics Corp (UTHR) detailing a proposed sale of securities. The filing shows an exercise of stock options by the issuer for 120,000 shares of common stock with an aggregate market value of $62,913,600.00. The transaction date and payment date for these securities are both listed as March 23, 2026.
Swiss Life Asset Management Ltd Lowers Stock Position in United Therapeutics Corporation $UTHR
Swiss Life Asset Management Ltd reduced its stake in United Therapeutics Corporation by 48.1% in the third quarter, selling 7,031 shares and now holding 7,599 shares valued at $3.19 million. Despite this, analysts maintain a "Moderate Buy" consensus with an average price target of $548.09, following recent upgrades from UBS, RBC, and Cantor Fitzgerald. Insiders, including the COO and CEO, have been significant net sellers, offloading shares worth approximately $156.8 million, while institutional ownership stands at about 94.08%.
If You Invested $1,000 in United Therapeutics Corp. (UTHR)
This article analyzes the historical performance of United Therapeutics Corp. (UTHR) stock, showing how a $1,000 investment would have grown over 1, 5, and 10 years, and includes a year-by-year return comparison against the S&P 500. It also provides a detailed overview of the company, its therapeutic focus in cardiopulmonary diseases and organ transplantation, its public benefit corporation status, and its commercial products and clinical pipeline. The article highlights UTHR's strong returns, outperforming the S&P 500 over the past decade, and details its market position and innovative projects in xenotransplantation.
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares under 10b5-1 plan
United Therapeutics (UTHR) CEO Martine Rothblatt exercised stock options for 9,500 shares at $146.03 per share and subsequently sold all 9,500 shares through multiple open-market transactions on March 19, 2026. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan, occurred at weighted-average prices ranging from approximately $524.62 to $532.90. Following these transactions, Rothblatt directly holds 40,513 shares and maintains significant indirect holdings via trusts and her spouse.
United Therapeutics stock faces headwinds from new study data on rival therapies amid pipeline advan
United Therapeutics (UTHR) stock faced headwinds following mixed data from a rival's pulmonary hypertension drug trial, raising concerns about market share despite UTHR's Treprostinil franchise showing steady growth. The company, a leader in PAH treatments, saw its shares dip after Liquidia Corporation's inhaled Treprostinil trial missed its primary endpoint. Despite this short-term win for United Therapeutics, investors are considering competitive risks as UTHR continues to advance its pipeline in organ manufacturing and other therapies.
Hudson Bay Capital Management LP Reduces Stock Position in United Therapeutics Corporation $UTHR
Hudson Bay Capital Management LP significantly reduced its stake in United Therapeutics Corporation (UTHR) by 67.1% in Q3. Despite this, institutional ownership remains high, with other major funds increasing their positions. Analysts maintain a largely positive outlook with an average price target of $548.09, but recent insider selling, including by the CEO, could put downward pressure on the stock.
How Investors May Respond To United Therapeutics (UTHR) IPF Trial Success And New Buyback Program
United Therapeutics (UTHR) recently announced positive Phase 3 trial results for nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF) and initiated a new US$2 billion share repurchase program. This success positions Tyvaso as a potential first-in-class inhaled anti-fibrotic treatment, strengthening UTHR's pulmonary franchise and investment narrative. Investors will be weighing these developments against regulatory decisions, competitive threats, and the company's reliance on core drugs, while analysts project significant revenue and earnings growth by 2028.
United Therapeutics (UTHR) CEO exercises options and sells 9,500 shares under plan
Martine Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), exercised stock options for 9,500 shares and subsequently sold them in open-market transactions. These actions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following these transactions, Rothblatt retains significant direct and indirect holdings in the company.
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company's stock for over $5 million, reducing her stake by 19% to 40,513 shares. This transaction followed United Therapeutics' Q earnings report, which exceeded EPS estimates but missed revenue forecasts. The stock currently trades near $527, with analysts maintaining an average "Moderate Buy" rating and a target price of around $548.
Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock
Paul Mahon, Executive VP of United Therapeutics, sold 8,300 shares of UTHR stock for over $4.39 million on March 19, reducing his holding by 15.52%. The company recently reported strong quarterly earnings, beating analyst estimates for EPS but slightly missing revenue forecasts, while maintaining a high net margin. Analysts generally have a "Moderate Buy" rating for United Therapeutics with a consensus target price of $548.09.
United Therapeutics CEO Rothblatt sells $5m in UTHR stock
Martine Rothblatt, CEO of United Therapeutics Corp, sold over $5 million in UTHR stock on March 18, 2026, while also exercising stock options. These transactions occurred as the company's stock trades near its 52-week high, supported by positive clinical trial results for its idiopathic pulmonary fibrosis treatment and a new $2 billion stock repurchase program. Analysts have raised price targets, reflecting confidence in the company's financial strategies and advancements.
[144] UNITED THERAPEUTICS Corp SE... | UTHR SEC Filing - Form 144
This SEC filing (Form 144) for UNITED THERAPEUTICS Corp (UTHR) reports the proposed sale of 45 shares of restricted Common Stock by an issuer-affiliated holder, Jan Malcolm. The filing also details several prior dispositions by the same holder, with 50-share sales occurring between December 2025 and March 2026. These transactions, filed under Rule 144, are deemed routine by a Securities Compliance Analyst.
Achmea Investment Management B.V. Has $10.11 Million Position in United Therapeutics Corporation $UTHR
Achmea Investment Management B.V. significantly reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 36.3% in the third quarter, now holding 24,105 shares valued at $10.11 million. Despite this reduction, other institutional investors have increased their positions. Wall Street analysts maintain a "Moderate Buy" consensus rating with an average target price of $548.09, and the company recently reported strong earnings, beating consensus estimates.
How Investors May Respond To United Therapeutics (UTHR) IPF Trial Success And New Buyback Program
United Therapeutics (UTHR) recently reported successful Phase 3 TETON-2 trial results for nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF), which could position it as the first inhaled anti-fibrotic treatment for the condition. This clinical success, alongside a new $2.00 billion share repurchase program, is expected to significantly influence the company's investment narrative. Investors will be assessing how these developments affect regulatory decisions, competitive landscape, and future cash flow, while also considering the company's dependence on its core drug portfolio.
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock
Martine Rothblatt, CEO of United Therapeutics (NASDAQ:UTHR), sold 9,500 shares of the company's stock on March 13, 2026, for a total of $5,111,000, reducing her ownership by 98.65%. Despite this significant insider sale, institutional investors own a substantial 94.08% of the company, with several large funds increasing their positions. United Therapeutics recently beat quarterly EPS estimates and holds a "Moderate Buy" consensus rating from analysts.
United Therapeutics Surges 12% Last Week: Why Street Sets a $592 Mean Target
United Therapeutics (UTHR) shares surged 12% last week to $537.60 following breakthrough clinical trial results for ralinepag, an oral pill for pulmonary arterial hypertension. The ADVANCE OUTCOMES Phase 3 trial demonstrated a 55% reduction in disease worsening, positioning ralinepag as a potential blockbuster with a projected $2 billion revenue by 2030. With two other major product launches expected in 2027 and a $2 billion stock buyback program, analysts have set a mean price target of $592.25, indicating further upside for the stock.
